Literature DB >> 15310726

Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases.

F Andersohn1, F G Hagmann, E Garbe.   

Abstract

Clopidogrel has been reported to be safe and effective in reducing vascular events. Nevertheless, there is growing evidence that clopidogrel may cause thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome (TTP/HUS). This association has been debated, since in several cases alternative causes could not be excluded. Two new cases of TTP/HUS associated with clopidogrel are reported here. After discontinuation of clopidogrel and treatment with plasma exchange, both patients had a complete and sustained recovery from TTP/HUS. These cases corroborate previous observations that clopidogrel may indeed be a rare cause of TTP/HUS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310726      PMCID: PMC1768406          DOI: 10.1136/hrt.2004.039214

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

Review 1.  Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review.

Authors:  W Nara; I Ashley; F Rosner
Journal:  Am J Med Sci       Date:  2001-09       Impact factor: 2.378

2.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

3.  Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors:  S R Steinhubl; W A Tan; J M Foody; E J Topol
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

5.  Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin).

Authors:  P B Berger; M R Bell; D E Grill; S Melby; D R Holmes
Journal:  Am J Cardiol       Date:  1998-03-15       Impact factor: 2.778

Review 6.  Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality.

Authors:  Navneet S Majhail; Alan E Lichtin
Journal:  Cleve Clin J Med       Date:  2003-05       Impact factor: 2.321

7.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

Authors:  W K Hass; J D Easton; H P Adams; W Pryse-Phillips; B A Molony; S Anderson; B Kamm
Journal:  N Engl J Med       Date:  1989-08-24       Impact factor: 91.245

  7 in total
  1 in total

Review 1.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.